These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17327932)

  • 1. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.
    Diakou MC; Liberopoulos EN; Mikhailidis DP; Tsianos EV; Burroughs AK; Elisaf MS
    Scand J Gastroenterol; 2007 Feb; 42(2):139-47. PubMed ID: 17327932
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment of non-alcoholic steatohepatitis.
    Kadayifci A; Merriman RB; Bass NM
    Clin Liver Dis; 2007 Feb; 11(1):119-40, ix. PubMed ID: 17544975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Feb; 98(2):495-9. PubMed ID: 12591075
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug therapy for nonalcoholic fatty liver disease].
    Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):139. PubMed ID: 15727706
    [No Abstract]   [Full Text] [Related]  

  • 6. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
    Ahmed MH; Osman KA
    Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
    [No Abstract]   [Full Text] [Related]  

  • 9. [Non-alcoholic steatohepatitis].
    Rakov AL; Gorbakov VV; Vecherinina OO
    Voen Med Zh; 2006 Jul; 327(7):33-9. PubMed ID: 16977879
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety].
    Bueverov AO; Bogomolov PO; Maevskaia MV
    Ter Arkh; 2007; 79(8):88-92. PubMed ID: 17926479
    [No Abstract]   [Full Text] [Related]  

  • 13. Obesity and cardiometabolic syndrome in children.
    Velasquez-Mieyer P; Neira CP; Nieto R; Cowan PA
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):61-81. PubMed ID: 19124396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeuric aspects of NAFLD. A literature review].
    Tapia NC; Avila FI; Leiva JG; Ramos MH; Avila JF; Uribe M
    Rev Gastroenterol Mex; 2006; 71(4):487-95. PubMed ID: 17542283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fatty liver and steatotic non-alcoholic hepatitis].
    Angulo P
    Rev Gastroenterol Mex; 2004 Nov; 69 Suppl 3():140-8. PubMed ID: 16881219
    [No Abstract]   [Full Text] [Related]  

  • 16. [News from the Cochrane Library: treatment of nonalcoholic fatty liver disease and steatohepatitis].
    Timmer A
    Z Gastroenterol; 2007 Feb; 45(2):191-3. PubMed ID: 17304406
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-alcoholic steatohepatitis: therapeutic management].
    Cadranel JF
    Gastroenterol Clin Biol; 2003; 27(8-9):799-805. PubMed ID: 14586251
    [No Abstract]   [Full Text] [Related]  

  • 19. 4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome.
    Jetté L; Harvey L; Eugeni K; Levens N
    Curr Opin Investig Drugs; 2009 Apr; 10(4):353-8. PubMed ID: 19337956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Place of hypoglycemic sulfonamides in treatment of steatosis of nutritional origin].
    Dorf G; Tutin M; Bour H; Guy-Grand B
    Therapeutique; 1969 May; 45(5):536-7. PubMed ID: 5791835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.